Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron plus celecoxib to prevent catheter-related bladder discomfort after TURBT
ChiCTR2600128768Phase 4Not yet recruiting
- Sponsor
- Third Xiangya Hospital, Central South University
- Start
- Jul 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in cystitis and cystospasm comparing Mirabegron plus celecoxib with Placebo (2 arms). Primary endpoints: Incidence of moderate-to-severe catheter-related bladder discomfort and Bladder Spasm Symptom Score. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
mirabegroncelecoxib
03
Conditions
cystitiscystospasm
Beyond the preview
Go deeper on ChiCTR2600128768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128768.